Stock analysts at StockNews.com initiated coverage on shares of Biocept (NASDAQ:BIOC – Get Rating) in a note issued to investors on Sunday. The firm set a “hold” rating on the medical research company’s stock.
Separately, Brookline Capital Management lowered Biocept from a “buy” rating to a “hold” rating in a report on Friday, January 6th.
Biocept Stock Performance
Shares of Biocept stock opened at $0.24 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 5.13 and a quick ratio of 4.86. The business has a 50-day simple moving average of $0.51 and a 200 day simple moving average of $0.68. The firm has a market capitalization of $4.02 million, a price-to-earnings ratio of -0.24 and a beta of 1.01. Biocept has a one year low of $0.24 and a one year high of $2.43.
Institutional Inflows and Outflows
Biocept Company Profile
Biocept, Inc is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample.
- Get a free copy of the StockNews.com research report on Biocept (BIOC)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with MarketBeat.com's FREE daily email newsletter.